ANDA 217583, held by Fresenius Kabi USA. Manganese Chloride.
As of Nov 16, 2026, ANDA 217583 (Manganese Chloride), held by Fresenius Kabi USA, was first approved by FDA on Jul 7, 2025, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Manganese chloride injection, USP is indicated for use in adult patients as a supplement to intravenous solutions given for TPN. Administration helps to maintain manganese serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 7, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Manganese ChlorideEQ 0.1MG MANGANESE/ML · injectable;injection | Manganese Chloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters